Note: This document contains side effect information about dolasetron. Some of the dosage forms listed on this page may not apply to the brand name Anzemet.
More frequent side effects include: dizziness. See below for a comprehensive list of adverse effects.
Applies to dolasetron: oral tablet
Other dosage forms:
Along with its needed effects, dolasetron (the active ingredient contained in Anzemet) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking dolasetron:
Some side effects of dolasetron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to dolasetron: intravenous solution, oral tablet
The most common side effects include headache, constipation, sleep disorders, and dizziness.
Loss of consciousness may occur immediately/closely after an IV bolus in patients receiving treatment for prophylaxis of chemotherapy induced nausea and vomiting.
Headache and dizziness occurred more frequently at higher doses.
Very common (10% or more): Headache (up to 41.1%), dizziness (up to 12.5%), drowsiness (up to 10.5%)
Rare (0.01% to 0.1%): Seizure, syncope
Frequency not reported: Taste perversion, vertigo, paresthesia, tremor, ataxia
Postmarketing reports: Loss of consciousness
Very common (10% or more): Constipation (up to 28.6%), dyspepsia (up to 12.8%), diarrhea (up to 11.1%), abdominal pain (up to 10.2%)
Rare (0.01% to 0.1%): Intestinal obstruction, pancreatitis
Very common (10% or more): Sleep disorder (up to 12.8%)
Frequency not reported: Agitation, depersonalization, confusion, anxiety, abnormal dreaming
Very common (10% or more): Fatigue (up to 12.2%)
Common (1% to 10%): Pain, fever, chills/shivering
Frequency not reported: Tinnitus
Postmarketing reports: Facial edema
Common (1% to 10%): Bradycardia (mostly sinus), hypotension, tachycardia (mostly sinus)
Uncommon (0.1% to 1%): Chest pain, orthostatic hypotension, hypertension
Rare (0.01% to 0.1%): Myocardial ischemia, edema
Frequency not reported: T wave change, ST-T wave change, sinus arrhythmia, extrasystole (atrial/ventricular premature contractions), poor R wave progression, left and right bundle branch block, nodal arrhythmias, U wave change, atrial flutter/fibrillation, peripheral edema, Mobitz I AV block, palpitations, peripheral ischemia, thrombophlebitis/phlebitis
Postmarketing reports: Severe hypotension, wide complex tachycardia, ventricular tachycardia, ventricular fibrillation/cardiac arrest, shock
Severe hypotension and bradycardia occurred immediately/closely after an IV bolus in patients receiving treatment for prophylaxis of chemotherapy induced nausea and vomiting.
Wide complex tachycardia, ventricular tachycardia, and ventricular fibrillation/cardiac arrest were rarely reported after IV administration.
Common (1% to 10%): Increased serum transaminases (AST, ALT)
Rare (0.01% to 0.1%): Jaundice
Frequency not reported: Hyperbilirubinemia, increased GGT
Increased serum transaminases occurred more frequently in patients treated during IV chemotherapy/radiotherapy than those treated during postoperative therapy/IV surgery; however, the increases did not appear to be related to dose/duration of therapy, and were not associated with symptomatic hepatic disease.
Respiratory side effects have rarely included dyspnea and bronchospasm.
Frequency not reported: Prothrombin time prolonged, partial thromboplastin time (PTT) increased, anemia, purpura/hematoma, thrombocytopenia
Frequency not reported: Hematuria, dysuria, urinary retention, polyuria
Frequency not reported: Increased sweating, flushing, rash
Postmarketing reports: Urticaria
Frequency not reported: Myalgia, arthralgia, twitching
Frequency not reported: Anorexia, increased alkaline phosphatase
Frequency not reported: Abnormal vision, photophobia
Frequency not reported: Acute renal failure
Postmarketing reports: Anaphylactic/anaphylactoid reactions, angioedema
Postmarketing reports: Local pain/burning (IV formulation)
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Anzemet